Tag Archives: Novartis halts hydroxychloroquine trial against COVID-19

Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data emerged from other studies raising doubts about its efficacy. Novartis’ trial began in April and sought to test the drug in 440 hospitalized patients. But the project only managed to recruit a handful. Novartis’ move follows …

Read More »